Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses is a research paper published in American Journal of Hematology (2020). On theSindex it has a DataRank of 0. It has been cited 29 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Lymphoma Research Foundation
Grant: None
National Institutes of Health
Grant: R01‐CA160979
NCI NIH HHS
Grant: R01 CA160979
NCI NIH HHS
Grant: R01 CA213442
FWCI
1.58
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals